La cadena de opciones muestra datos clave de las opciones de acciones de Arcadia Biosciences a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Arcadia Biosciences..

Arcadia Biosciences (NASDAQ:RKDA) Bolsa, Cadena de Opciones

Arcadia Biosciences

Arcadia Biosciences Inc is a producer and marketer of plant-based food and beverage products. It is engaged in science-based approaches to developing high-value crop improvements in wheat, soy, and hemp, designed to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients, health, and wellness products, and their viability for industrial applications. The company's consumer brands in the food, beverage, and body care categories include GoodWheat high-fiber pasta, Zola coconut water, and others.

Arcadia Biosciences Inc

SELLAS Life Sciences Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLS#NASDAQ">SLS</a>) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.10) by 30 percent. This is a 66.67 percent increase over losses of $(0.21) per share from the same period last year.

Earnings

Earnings Beats

News

SELLAS Life Sciences Gr Q1 EPS $(0.07) Beats $(0.10) Estimate

Offerings

LOAR

Loar Launches Secondary Public Offering Of 9M Shares

DiaMedica Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMAC#NASDAQ">DMAC</a>) reported quarterly losses of $(0.18) per share which met the analyst consensus estimate. This is a 28.57 percent decrease over losses of $(0.14) per share from the same period last year.

DMAC

DiaMedica Therapeutics Q1 EPS $(0.18), Inline

64% (9/14) complete response rate with AlloNK + rituximab in heavily pretreated patients that were naïve to prior CAR-T cell therapy, in line with approved auto-CAR-T therapies in aggressive B-NHL
Median duration of response for AlloNK + rituximab not yet reached and is at least 19.4 months, in line with approved auto-CAR-T therapies in aggressive B-NHL
AlloNK's activity and well-tolerated safety profile in aggressive B-NHL patients support the potential to deliver deep B-cell depletion in a refractory autoimmune population in outpatient community settings
SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARTV#NASDAQ">ARTV</a>), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced new longer-term Phase 1/2 data demonstrating durable responses for AlloNK&#xAE; (also known as AB-101) in combination with rituximab (RTX) in patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) at the American Society of Gene &amp; Cell Therapy (ASGCT) 28th annual meeting.

Biotech

General

ARTV

Artiva Biotherapeutics Announces Longer-Term Phase 1/2 Data Demonstrating Prolonged Durability For AlloNK In Combination With Rituximab In Patients With B-cell-Non-Hodgkin Lymphoma At The ASGCT 28th Annual Meeting

Arteris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIP#NASDAQ">AIP</a>) widens FY2025 sales outlook from $66.00 million-$70.00 million to $65.00 million-$71.00 million vs $68.40 million estimate.

Guidance

Arteris Widens FY2025 Sales Guidance from $66.00M-$70.00M to $65.00M-$71.00M vs $68.40M Est

CACI International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CACI#NYSE">CACI</a>) has outperformed the market over the past 10 years by 7.21% on an annualized basis producing an average annual return of 17.87%. Currently, CACI International has a market capitalization of $10.16 billion. 
Buying $100 In CACI: If an investor had bought $100 of CACI stock 10 years ago, it would be worth $518.27 today based on a price of $462.04 for CACI at the time of writing.
<h3>CACI International's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747168214_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

CACI

$100 Invested In CACI International 10 Years Ago Would Be Worth This Much Today

Arteris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIP#NASDAQ">AIP</a>) sees Q2 sales of $16.100 million-$16.500 million vs $15.90 million analyst estimate.

Arteris Sees Q2 Sales $16.100M-$16.500M vs $15.90M Est

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/VFF">Village Farms Intl</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>) shares closed up 35.12% at $0.96</li>
<li><a href="https://www.benzinga.com/quote/TGIFF">1933 Industries</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TGIFF#OTC">TGIFF</a>) shares closed up 25.00% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CWBHF">Charlottes Web Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CWBHF#OTC">CWBHF</a>) shares closed up 17.28% at $0.10</li>
<li><a href="https://www.benzinga.com/quote/CXXIF">C21 Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CXXIF#OTC">CXXIF</a>) shares closed up 10.57% at $0.15</li>
<li><a href="https://www.benzinga.com/quote/BBRRF">Blueberries Medical</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BBRRF#OTC">BBRRF</a>) shares closed up 9.70% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/FFNTF">4Front Ventures</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed up 7.14% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CURLF">Curaleaf Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>) shares closed up 5.89% at $0.87</li>
<li><a href="https://www.benzinga.com/quote/SOL">Emeren Group</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOL#NYSE">SOL</a>) shares closed up 5.26% at $1.60</li>
<li><a href="https://www.benzinga.com/quote/CVSI">CV Sciences</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CVSI#OTC">CVSI</a>) shares closed up 5.08% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/TCNNF">Trulieve Cannabis</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTC">TCNNF</a>) shares closed up 4.65% at $4.50</li>
<li><a href="https://www.benzinga.com/quote/GBHPF">Global Hemp Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GBHPF#OTC">GBHPF</a>) shares closed up 4.35% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CNTMF">FLUENT</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTC">CNTMF</a>) shares closed up 3.78% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/XXII">22nd Century Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) shares closed up 3.74% at $1.15</li>
<li><a href="https://www.benzinga.com/quote/SMG">Scotts Miracle Gro</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMG#NYSE">SMG</a>) shares closed up 3.51% at $59.00</li>
<li><a href="https://www.benzinga.com/quote/ESE">ESCO Technologies</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESE#NYSE">ESE</a>) shares closed up 3.25% at $185.41</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/LBUY">Leafbuyer Techs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LBUY#OTC">LBUY</a>) shares closed down 13.00% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/RMHB">Rocky Mountain High</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed down 12.12% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/GNLN">Greenlane Hldgs</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) shares closed down 10.83% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CLSH">CLS Holdings USA</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CLSH#OTC">CLSH</a>) shares closed down 10.70% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/OILFF">Nextleaf Solutions</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OILFF#OTC">OILFF</a>) shares closed down 8.09% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/CBWTF">Auxly Cannabis Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBWTF#OTC">CBWTF</a>) shares closed down 4.62% at $0.06</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cannabis

Markets

Movers

BBRRF

CANNABIS WHEATON INCOME by Cannabis Wheaton Income Corp.

CBWTF

CLSH

CNTMF

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

CVSI

CWBHF

CXXIF

FFNTF

GBHPF

GNLN

LEAFBUYER TECHNOLOGIES by Leafbuyer Technologies, Inc.

LBUY

OILFF

RMHB

TCNNF

TGIFF

XXII

Cannabis Stock Gainers And Losers From May 13, 2025

KinderCare Learning (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLC#NYSE">KLC</a>) affirms FY2025 Adj EPS guidance from $0.75-$0.85 to $0.75-$0.85 vs $0.79 analyst estimate. Affirms FY2025 sales outlook from $2.75 billion-$2.85 billion to $2.75 billion-$2.85 billion vs $2.81 billion estimate.

KinderCare Learning Affirms FY2025 Adj EPS Guidance of $0.75-$0.85 vs $0.79 Est; Affirms FY2025 Sales Guidance of $2.75B-$2.85B vs $2.81B Est

Arteris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIP#NASDAQ">AIP</a>) reported quarterly losses of $(0.09) per share which met the analyst consensus estimate. This is a 40 percent increase over losses of $(0.15) per share from the same period last year. The company reported quarterly sales of $16.53 million which beat the analyst consensus estimate of $15.90 million by 3.97 percent. This is a 27.69 percent increase over sales of $12.95 million the same period last year.

Arteris Q1 Adj. EPS $(0.09), Inline, Sales $16.53M Beat $15.90M Estimate

Exchangeable for Class A Common Stock of Aurora Innovation, Inc.
Uber Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) today announced that it intends to offer, subject to market conditions and other factors, $1.0 billion principal amount of Exchangeable Senior Notes due 2028 (the "notes") in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Uber also intends to grant the initial purchaser of the notes an option to purchase up to an additional $150 million principal amount of the notes.
The notes will be exchangeable into cash, or, subject to the satisfaction of certain share delivery conditions, units of reference property, or a combination of cash and units of reference property, at Uber's election. Initially, each unit of reference property will be comprised of one share of Class A common stock, par value $0.00001 per share, of Aurora Innovation, Inc. ("Aurora common stock"). The interest rate, initial exchange rate, repurchase rights, redemption rights and other terms of the notes will be determined at the time of pricing of the offering.
The notes will be Uber's senior obligations and will be secured by first-priority liens on certain pledged reference property held by Uber's indirect wholly owned subsidiary, Neben Holdings, LLC ("Neben") (which pledged reference property will initially consist of the maximum number of shares of Aurora common stock deliverable upon exchange of the notes). The notes will be guaranteed by Neben on a limited recourse basis to the extent of the pledged reference property.

UBER

Uber Announces Proposed Private Placement Of $1B Of Exchangeable Senior Senior Notes Due 2028

KinderCare Learning (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLC#NYSE">KLC</a>) reported quarterly earnings of $0.23 per share which beat the analyst consensus estimate of $0.17 by 35.29 percent. The company reported quarterly sales of $668.24 million which missed the analyst consensus estimate of $680.94 million by 1.86 percent.

Earnings Misses

KinderCare Learning Q1 Adj. EPS $0.23 Beats $0.17 Estimate, Sales $668.24M Miss $680.94M Estimate

Genasys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNSS#NASDAQ">GNSS</a>) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.12) by 16.67 percent. This is a 12.5 percent increase over losses of $(0.16) per share from the same period last year. The company reported quarterly sales of $6.93 million which missed the analyst consensus estimate of $8.03 million by 13.71 percent. This is a 20.79 percent increase over sales of $5.74 million the same period last year.

GNSS

Genasys Q2 EPS $(0.14) Misses $(0.12) Estimate, Sales $6.93M Miss $8.03M Estimate

a.k.a. Brands Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AKA#NYSE">AKA</a>) reported quarterly losses of $(0.78) per share which beat the analyst consensus estimate of $(0.82) by 4.88 percent. This is a 8.24 percent increase over losses of $(0.85) per share from the same period last year. The company reported quarterly sales of $128.66 million which beat the analyst consensus estimate of $122.37 million by 5.14 percent. This is a 10.11 percent increase over sales of $116.84 million the same period last year.

a.k.a. Brands Holding Q1 EPS $(0.78) Beats $(0.82) Estimate, Sales $128.66M Beat $122.37M Estimate

Elicio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELTX#NASDAQ">ELTX</a>) reported quarterly losses of $(0.87) per share which missed the analyst consensus estimate of $(0.83) by 4.82 percent. This is a 24.35 percent increase over losses of $(1.15) per share from the same period last year.

ELTX

Elicio Therapeutics Q1 EPS $(0.87) Misses $(0.83) Estimate

KVYO

Klaviyo Announces  $372,000,000 Proposed Secondary Offering By CEO And Founder Andrew Bialecki

DoubleDown Interactive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDI#NASDAQ">DDI</a>) reported quarterly earnings of $0.48 per share which missed the analyst consensus estimate of $0.55 by 12.73 percent. This is a 21.31 percent decrease over earnings of $0.61 per share from the same period last year. The company reported quarterly sales of $83.49 million which missed the analyst consensus estimate of $84.94 million by 1.71 percent. This is a 5.28 percent decrease over sales of $88.14 million the same period last year.

DoubleDown Interactive Q1 earnings per ADS $0.48 Misses $0.55 Estimate, Sales $83.49M Miss $84.94M Estimate

Transact Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TACT#NASDAQ">TACT</a>) affirms FY2025 sales outlook from $47.00 million-$52.00 million to $47.00 million-$52.00 million vs $47.93 million estimate.

TACT

Transact Technologies Affirms FY2025 Sales Guidance of $47.00M-$52.00M vs $47.93M Est

<a href="https://www.bloomberg.com/news/articles/2025-05-13/southwest-air-hints-at-international-expansion-in-dot-request" title="https://www.bloomberg.com/news/articles/2025-05-13/southwest-air-hints-at-international-expansion-in-dot-request">https://www.bloomberg.com/news/articles/2025-05-13/southwest-air-hints-at-international-expansion-in-dot-request</a>

'Southwest Air Hints at International Expansion in DOT Request' - Bloomberg News

Rezolute (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLT#NASDAQ">RZLT</a>) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.23) by 17.39 percent. This is a 20.59 percent increase over losses of $(0.34) per share from the same period last year.

RZLT

Rezolute Q3 EPS $(0.27) Misses $(0.23) Estimate

Press Releases

ARCADIA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Arcadia Biosciences, Inc. - RKDA

Legal

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFIE, CDMO, RKDA on Behalf of Shareholders

$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger - EVGR, QTRX, RKDA, EBTC

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RDW, EBTC, RKDA on Behalf of Shareholders

RKDA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Arcadia Biosciences, Inc. is Fair to Shareholders

Arcadia Biosciences (RKDA) Announces Date of Fourth Quarter 2024 Financial Results and Business Highlights Conference Call

Arcadia Biosciences (RKDA) Announces Fourth-Quarter and Full-Year 2024 Financial Results and Business Highlights

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RKDA, CKPT, QTRX on Behalf of Shareholders

Arcadia Biosciences (RKDA) Announces Date of First Quarter 2025 Financial Results and Business Highlights Conference Call

Arcadia Biosciences (RKDA) Announces First Quarter 2025 Financial Results and Business Highlights

CDMO

CKPT

EBTC

EVGR

PFIE

QTRX

RKDA

Archer-Daniels-Midland Company Common Stock

Archer-Daniels-Midland

AgriFORCE Growing Systems Ltd. - Common Shares

AgriFORCE Growing Systems

Alico

Bunge Global

Cresud S.A.C.I.F. y A. - American Depositary Shares, each representing ten shares of Common Stock

Comments

Arcadia Biosciences

Arcadia Biosciences (RKDA) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL